AbstractÐThe fatality rate associated with severe bacterial infections is about 30 percent and appropriate antibiotic treatment reduces it by half. Unfortunately, about a third of antibiotic treatments prescribed by physicians are inappropriate. We have built a causal probabilistic network (CPN) for treatment of severe bacterial infections. The net is based on modules, each module representing a site of infection. The general configuration of a module is as follows: Major distribution factors define groups of patients, each of them with a definite prevalence of infection caused by a given pathogen. Minor distribution factors multiply the likelihood of one pathogen, without changing much of the prevalence of infection. Infection caused by a pathogen causes local and generalized signs and symptoms. Antibiotic treatment is appropriate if it matches the susceptibility of the pathogens in vitro and appropriate treatment is associated with a gain in life expectancy. This is balanced against the cost of the drug, side effects, and ecological damage, to reach the most cost effective treatment. The net was constructed in such a way that the data for the conditional probability tables will be available, even if it meant sometimes giving up on fine modeling details. For data, we used large databases collected by us in the last 10 years and data from the literature. The CPN was a convenient way to combine data from databases collected at different locations and times with published information. Although the net is based on detailed and large databases, its calibration to new sites requires data that is available in most modern hospitals.
INTRODUCTION
T HE fatality rate associated with severe bacterial infections is about 30 percent [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] . Antibiotic drugs are the mainstay of treatment in this condition. Patients treated with appropriate and early antibiotic treatment have a much better chance of survival than patients given inappropriate antibiotics or no antibiotics at all [1] , [3] , [6] , [7] , [8] .
The suspicion of a severe bacterial infection is usually raised because of nonspecific complaints, the main one being fever. Within the first hour of encountering such a patient, the physician should decide whether the likelihood of a bacterial infection is high enough to start early (and empirical) antibiotic treatment, whether the infection is severe enough to warrant intravenous treatment, and, if so, which antibiotic drug(s) to prescribe.
To reach these decisions, the physician is aided by several time-honored associations. The likelihood of a bacterial infection is assessed by the presence of evidence in favor of a localized infection (e.g., an infection of the urinary tract or pneumonia) and by signs and symptoms that are more closely associated with a bacterial infection than with other causes of fever. The severity of infection is estimated mainly by its influence on blood pressure, capillary permeability, and oxygen supply to vital organs (kidneys, lungs, brain). These are mediated through responses of the body and are not specific to the infection [9] .
To choose an antibiotic drug, the physician should appraise which are the most likely pathogens of infection, and what their susceptibility to antibiotics is. The main determinant of the pathogen is the site of infection (e.g., urinary tract or the lungs), in addition to other factors, such as the place of acquisition of the pathogen causing the infection (hospital or community), defects in the patient's defense mechanisms, etc. [10] . The patterns of susceptibility to antibiotics differ from region to region and from hospital to hospital. Even in the same hospital, different units have distinct patterns of susceptibility. The main predictor of resistance that is related to the individual patient is whether he has been treated with antibiotics before the present infection [11] .
Last, the physician should balance the benefits associated with each antibiotic drug against its detriments. The benefits are coverage (given the likely pathogens and their susceptibility to antibiotics) and activity at the site of infection. These can be translated into a reduction in mortality and morbidity [6] . [8] . The detriments are the cost of the drug, side effects, and development of resistance.
Unfortunately, the results of these mental computations are often erroneous. About a third of patients with severe bacterial infections are given inappropriate empirical antibiotic treatment and 20 percent are prescribed superfluous drugs [8] , [12] , [13] . Moreover, the overall balance of antibiotic treatment vs. pathogens is tipping worldwide to the wrong side. Antibiotic drugs account for 20 to 50 percent of a hospital's pharmaceutical expenditure [14] . Resistance to antibiotics is a major problem [15] and strains of bacteria resistant to almost all drugs are emerging [16] , [17] . The last major new group of antibiotic drugs was introduced into clinical practice more than a decade ago.
A simple computerized decision support system (DSS) employed at LDS Hospital, Salt Lake City, Utah, was shown to improve antibiotic therapy of individual patients while reducing the costs related to antibiotic treatment and probably curbing the development of resistance [18] , [19] . Our experience was similar. We showed that inappropriate antibiotic treatments are biased and that five pathogens accounted for 60 percent of inappropriate treatments, but for only 20 percent of appropriate ones [12] . We built a DSS that was based on the basic distribution of pathogens in our hospital. It used likelihood ratios derived by logistic regression analysis from our databases to adjust the ranking of the five pathogens and to look for patients at high risk of harboring a resistant microorganism. The DSS outperformed the attending physicians at guessing the pathogen of the infection and its susceptibility to antibiotics. It reduced the percentage of inappropriate treatments by half, while prescribing fewer broad-spectrum and costly antibiotics [10] .
One problem with the system became evident on analyzing the results. The physician supplied the site of infection to the DSS and, in 20 percent of cases, it was incorrect. A second (and major) problem emerged when trying to transfer the DSS to another location [20] . The adjustment of the logistic models on which the DSS was based to another location required databases similar in size and detail to our original one; although it was quite clear that some factors are universal, some are only local and some needed to be changed.
Nevertheless, it seemed likely that better use of knowledge and data through a computerized DSS can improve the management of patients with severe bacterial infections, while reducing the use of broad-spectrum and costly antibiotics [10] , [18] , [19] . To obviate the problems of the previous DSSs, we decided to build a normative system, where a causal probabilistic network (CPN) was used to calculate the probability distributions for the relevant output variables and decision theory was used to balance the therapeutic benefit of antibiotic therapy against the detriments associated with antibiotic drugs.
CPNs have been proposed as useful knowledge representation in medicine [21] , [22] , [23] and have been used for diagnosis [24] , [25] and, in combination with decision theory, also for advising on therapy [26] . One of the advantages of using CPNs to represent knowledge is that knowledge derived from literature can be integrated smoothly with data derived from case databases, a property that will be exploited extensively.
OBJECTIVES
The aim of our project was to build a DSS for treatment of patients suspected of harboring a moderate to severe bacterial infection, based on a CPN. An explicit distinction was to be made between local and universal factors, so the calibration of the system to new sites will be natural.
We intended to build a normative system (i.e., corresponding to the real distribution of the population). The input of the DSS should be simple data, readily known or obtainable within hours of suspecting an infection. The outputs the DSS was planned to supply were:
1. the likelihood of a bacterial infection, 2. a measure of its severity, 3. the most likely site of infection, 4. the most likely pathogen(s), 5. the susceptibility of the pathogens to antibiotic drugs, 6. the gain in life expectancy of the patient related to the treatment with a specific antibiotic drug, 7. the cost of the antibiotic drug, including purchase, side effects, and ecological impact on future resistance, and 8. ranking of the antibiotic drugs according to a summation of 6 and 7, i.e., a cost-effectiveness index.
RESOURCES AND METHODS
To obtain the needed data, we used (besides the literature cited below) databases that were collected prospectively by us since 1988. Databases that are available to us include data on approximately 4,000 bacteremic patients seen at Beilinson Campus (Petah-Tiqva, Israel) [6] and about 1,000 bacteremic patients detected in the County of Northern Jutland, Denmark [8] ; about 1,400 patients suspected of harboring a moderate to severe bacterial infection [10] ; about 400 young women with urinary complaints [27] , [28] ; and 250 patients with urinary tract infections [29] . The details on each patient included demographic data, underlying disorders, presentation of infection, pathogen and its susceptibility to antibiotics, treatment, and outcome. The CPN was built with the use of a graphic interface for building of CPNs (HUGIN, Hugin Inc., Aalborg, Denmark). For data handling and analysis, we used the SAS software (SAS Inc., Cary, North Carolina).
GLOSSARY
Empirical antibiotic treatment: Treatment prescribed before the results of cultures or serological tests (that can point at the pathogen of infection) are known by making an educated guess as to the most likely pathogen and its susceptibility to antibiotics.
Pathogen: A microorganism capable of causing infection in humans.
Resistance and susceptibility to antibiotic drugs: The susceptibility of a microorganism to antibiotic drugs is tested in-vitro, usually by culturing the microorganism on an agar plate on which paper disks impregnated with a fixed amount of an antibiotic drug were placed. The zone of growth-inhibition around the disk is relative to the susceptibility. A second technique, more expensive and laborious, is to measure the growth of a microorganism in a liquid medium, under exposure to increasing concentrations of an antibiotic drug. There is a good correlation between susceptibility in-vitro and clinical response.
Coverage: The percentage of pathogens of a given infection susceptible to an antibiotic drug.
Plasmid: A ring-like fragment of DNA in bacteria, which can be transferred horizontally to another bacterium by conjugation. Many of the genes resistant to antibiotics reside on plasmids.
A GENERAL MODEL FOR A SITE OF INFECTION
The CPN was built from distinct modules, each module representing one site of infection. Fig. 1 depicts a general model of a site of infection. Pathogen1 to Pathogen_n represent the potential pathogens of infections at the given site. The states of the Pathogen nodes are severity states, with a risk of mortality associated with each state.
The probability of an infection caused by a Pathogen is determined by its prevalence in major patient-groups (M_Distrib_1 to M_Distrib_3). We selected a factor as defining a major patient-group (a major distribution factor) if it emerged as a strong and independent predictor for infection and distribution of pathogens on statistical analysis of our databases, if, according to present knowledge, it has a clear patho-physiological contribution to the risk of infection at this site, and if the data on the prevalence of infection and distribution of severity-states and pathogens are available.
Several factors qualified as minor distribution factors (Minor), i.e., factors that change the likelihood of one (or a few pathogens) without affecting the overall risk for infection.
Overall, the percentage of polymicrobial infections predicted by the net is less than found in our databases. To overcome this, we need node(s), which link some (or all) of the Pathogen nodes and indicate a breach in the defense mechanisms that is not specific for one pathogen (these nodes are not shown in Fig. 1 ). Thus, an increase in the likelihood of one pathogen will increase (by a small amount) the likelihood of other pathogens that are linked to it, enough to reach the expected prevalence of polymicrobial infections. For some sites, a mechanism can be postulated for this node (e.g., aspiration for infections of the lungs).
Any of the pathogens can cause an infection and infections can manifest as different patterns (Infection1 and Infection2). Infection will cause a local response (Local_respo), specific to each site of infection, and the local response will manifest as local signs and symptoms, e.g., cough and pains on inspiration caused by pneumonia (Local_sign1 to Local_sign3). It will also cause a systemic response (Sys_respon) common to all sites of infection and manifesting as generalized signs and symptoms (Sign1 to Sign3), such as fever, rapid pulse, and hypotension.
A pathogen causing an infection will grow in local specimens (e.g., urine or sputum, Spec_cultur) and in the blood (Blood_cultu). It can cause other changes, detectable by tests and specific for the site (e.g., leukocytes in the urine, Lab_site).
Antibiotic treatment (Antibiotic_tr) will be appropriate (Coverage) if it matches the in-vitro susceptibility of the pathogens and if it reaches appropriate levels in the blood and at the site of infection. The in-vitro susceptibility is determined by the pathogen and by local factors (mainly time and place of acquisition of infection and prior antibiotic treatment, Resistance).
The net gain in life expectancy obtained by prescribing an antibiotic drug (Gain) is determined by the Coverage and by the underlying disorders of the patient (Underlying). Cost is a utility node associated with antibiotic treatment. For each possible choice of antibiotic therapy, the cost node accounts for the total cost associated with the use of the antibiotic, including the cost of purchasing, side effects, and ecological impact. It is assumed that the best antibiotic therapy is the one with the highest net gain, where the net gain is calculated as the gain minus the cost.
In a complete net that includes all major sites of infection, the sites of infection ªcompeteº with each other to explain the systemic response (Sys_respon), positive blood-cultures (Blood_cultu), and other signs or symptoms that may be common to many sites. Local signs and symptoms (Local_sign1 to Local_sign3), and site-specific laboratory tests (Lab_site) will argue strongly in favor of a specific site. In their absence, the a priori prevalence of infections in the population takes precedence. The overall Gain constitutes from the gain at each site. Most of the time, one site will predominate.
EXAMPLE OF A SPECIFIC SITE: INFECTIONS OF
THE URINARY TRACT Fig. 2 depicts a net for urinary tract infections (UTI). For simplicity's sake, only five of 12 pathogens are presented, and some of the other nodes (e.g., some minor distribution factors and the details on blood cultures) were omitted. In this version, the net was calibrated for Beilinson Hospital, Petah-Tiqva, Israel.
Prevalence of Infection and Distribution of Pathogens
As an approximation for prevalence of new infections, we used daily incidence. The major determinants for the incidence of UTI and the distribution of the pathogens are the place and time of acquisition of infection (Acquisition), gender (Sex), and the presence of an indwelling urinary catheter (U_Catheter) [29] . The states of these nodes are given in Table 1 . The states of the pathogen nodes (Escherichia coli (E_coli), Klebsiella pneumoniae (Klebsiella), etc.) are detailed in Table 2 . Thus, we are looking at an V Â P Â P table for each pathogen. The source of data for each layer is given in Table 3 . Obtaining the data involves two separate questions: What is the incidence of UTI in a given patient-group (e.g., what is the percentage of women without a catheter in the community that have asymptomatic UTI, cystitis, etc.) and what is the percentage of UTI caused by the specific pathogen? The first question probably addresses universal factors: We can assume that the predisposition to infection and its severity are related to biological risk-factors, which are not much different all over the world. Table 3 details the sources of data for the incidence of urinary tract infections according to the major distribution factors. The only item for which data was completely missing in our databases Fig. 2) was the incidence of asymptomatic bacteriuria and that was drawn from the literature [30] , [32] , [34] , [36] , [37] , [39] , [41] , [42] , [45] . For the rest of the data, we calculated incidence data from our databases (number of infections per year per population in our cachement area), but checked that the data was within the interval reported in the literature (Table 4) .
The frequency of pathogens and susceptibility to antibiotics are specific to the location. Thus, the answer to the second question can be obtained entirely from our databases, but for the distribution of bacteria that cause asymptomatic bacteriuria. An example, part of the final conditional probability table for the node E_coli, is given in Table 5 .
The minor distribution factor shown in Fig. 2 is an antibiotic treatment prior to the infection (Antibiotics). Prior antibiotic treatment multiplies the likelihood of an infection caused by Pseudomonas aeruginosa (Pseudomon) by a factor of P. This ratio is a result of multivariable logistic analyses and independent of other factors [29] , [52] . We assumed that the net effect of prior antibiotic treatment on the prevalence of UTI is negligible.
The a priori distribution for the parent nodes was obtained from official publications (male: female ratios, age distribution, and number of hospital and nursing beds in the Beilinson cachement area [53] , [54] ); literature (percentage of people with an indwelling urinary catheter in and out of hospital [55] , [56] and percentage of prior antibiotic treatment in the general population and in inpatients [57] , [58] ).
Signs and Symptoms of Urinary Tract Infection: Local Manifestations
The manifestations of UTI do not depend on the pathogen. The local complaints associated with UTI are dysuria (burning on urination, Dysuria), frequent micturition (Frequency), urgency (Urgency), suprapubic pain (Supra), and incontinence (Incontinenc). The main problem with using the presence of these complaints to favor a bacterial UTI is that the complaints are highly correlated. If we were to count them separately, we will grossly exaggerate the strength of the evidence in favor of UTI.
To address these problems, we performed a factor analysis on the matrix of urinary complaints in patients with urinary complaints and UTI. Factor analysis builds new axes (factors), perpendicular to each other, where each factor represents correlations between variables. Thus, the dimensions of the matrix are reduced while keeping as much as possible of the original variance. Two factors explained more than 80 percent of the variance in the urinary complaints matrix. The first represented the correlation of dysuria, frequency, and suprapubic pain. The variables that contributed to the second factor were frequency and incontinence (Table 6 ). We dichotomized the factors by using the mean of the factor as the division point.
Thus, the following net was reached: UTI causes urinary symptoms (Urinary_sy), which causes Dys_factor, a nonobservable factor. Dys_factor causes Dysuria, Frequency, Urgency, and Supra (suprapubic pain). Urinary_sy also causes a second nonobservable factor, Incont_factor, which leads to complaints of frequency and incontinence. (Fig. 2) .
Flank pain (Flank) is a sign of kidney infection and the data was derived directly from our databases. The percentage of leukocyturia (Leukocyturi) and hematuria (Hematuria) in patients with UTI (the presence of white and red blood cells in the urine) was similar in our databases and in the literature [48] , [59] , [60] . To complete the tables, the percentage of each urinary symptom, leukocyturia, and hematuria in the general population (without urinary infections) was abstracted from the literature [56] , [59] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] .
Signs and Symptoms of Urinary Tract Infection: Systemic Response
The systemic response to infection affects many clinical variables (temperature, pulse, blood pressure, white blood cell count, serum creatinine, urea, and albumin, etc.). These The states were defined in such a way as to correspond to conventional clinical entities, but also to outline groups with a fixed and increasing likelihood of fatality (associated with the infection) and bacteremia.
variables are again highly correlated. Factor analysis showed four factors to account for more than 80 percent of the variance of the original matrix:
1. BP_Shock: The variables contributing to these factors were blood pressure (BP), evidence of disseminated intravascular coagulopathy (DIC), and evidence of other end-organs involvement (End_Organ). 2. Fever_factor: Main contributions from body temperature on admission (Fever) and the presence of chills (Chills). 3. Leuko: A factor that shows a correlation between the white blood cell count (WBC_Count) and serum creatinine (Creatinine). 4. Alb_factor: Main contributions from serum albumin (Albumin), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
Data were obtained from the local databases and information on the distribution of the body temperature, serum creatinine and albumin, erythrocyte sedimentation rate, etc., in the normal populationÐfrom the literature [69] , [70] , [71] , [72] , [73] . To give an example of the conditional probabilities, Table 7 shows the dependency of Fever_factor on UTI and Table 8 the conditional probability of Fever, given Fever_factor.
The four factors are statistical constructs. The inflammatory systemic effects are caused by mediators (mostly cytokines) released by macrophages in response to bacterial products [9] . Carlstedt et al. [74] tested the levels of the two main proinflammatory cytokines, tumor necrosis factor ; (xpE;) and interleukin 6 (IL-6), in a group of 140 patients. We performed a factor analysis on their data with similar results to our own. It was of interest to note that IL-66 had a major contribution to the Fever_factor (loading of HXWI) and to no other factor, while xpE; contributed to the BP_Shock factor (loading of HXSH). Thus, Fever_factor can be renamed as IL-6 and given real units and xpE is probably a major cause of BP_Shock. This preliminary analysis shows that the four factors are not peculiar to our databases and that the statistical constructs have biological correspondences which can be measured.
Urinary Tract Infection: Bacteriological Tests
Growth of microorganisms in the urine can be currently detected by two means. Some pathogens reduce nitrate to nitrite and that can be detected by a simple dipstick test. The sensitivity and specificity of the nitrite test (Nitrite) for each pathogen was derived from the literature [75] , [76] , [77] . The urine can be cultured on an agar plate (Urine_Cultu). The false positive rate of a growth on agar is about 20 percent because of external contamination of the urine. This is the number of patients in our database with a positive urine culture, but no other evidence of UTI, out of the total number of patients with positive cultures. The false negative rate is again about 20 percent. To reach this number, we looked at patients with urinary complaints, leukocytes in the urine, a positive blood culture, and a negative urine culture, out of the total number of patients with bacteremic UTI. Growth of microorganisms in the blood (Blood_Grow) is detected by injecting 20 ml of asseptically drawn blood into two bottles (a set) containing different growth media. The procedure is repeated two to three times (Blood_cul1 to Blood_cul3). The bottles are incubated and growth is detected automatically by an increase in infrared adsorption caused by a rise of gy P in the bottle. The fluid in the bottle is stained to look for microorganisms and it is cultured again on agar plates to identify the microorganisms and to test for susceptibility to antibiotics. Local data was used to assess the false positive and false negative rates of each step and to predict the pathogen by its features in the stained preparation. The total of each column is 1,000 patients.
Antibiotic Treatment: Resistance, Coverage, and Gain
The susceptibility of a pathogen to antibiotic drugs is determined by intrinsic factors of the pathogen and by acquired features. The strongest predictors of resistance are acquisition of infection in the hospital and antibiotic treatment in the month preceding the present infection [11] . Usually, a single antibiotic drug is prescribed, but treatment of severe infections with two drugs is not unusual. There are three reasons commonly given for that: 1) to increase the spectrum covered by empirical antibiotic treatment; 2) to use drugs that are synergistic; and 3) to try and prevent the development of resistance to one drug. Resistance to different antibiotic drugs is not independent, mainly because the genetic information on resistance to several drugs can be transmitted on the same plasmid. Thus, the coverage afforded by two drugs is not a simple multiplication of their coverage, but usually less than that, and should be derived from local data.
Therefore, the coverage of a pathogen (Coverage) depends on whether the pathogen caused an infection or not (the pathogen node, e.g., E_coli), which antibiotic(s) were prescribed (Antibiotic_tr), whether the infection was acquired in the hospital, and whether the patient was given prior antibiotic treatment (Resistance). We included in the net 26 antibiotic drugs that are used for treatment of moderate to severe infections and one additional state for no treatment. Thus, we are looking at a table of PU Â PU Â Q. However, some of the cells are a priori empty, as certain drugs are used only against a few microorganisms and not against others. Local data on the susceptibility of pathogens in the different subgroups were available from microorganisms that grew in blood-cultures.
Given the underlying condition of the patient (Underlying), including data on age, functional capacity, neutropenia, malignancy, atherosclerotic heart disease, congestive heart failure, serum albumin and creatinine, and sex, we can calculate the patient's life expectancy [6] . Coverage by an antibiotic drug will increase the chance of a 30-day survival by an odds-ratio of IXT [78] . Thus, we can calculate in life years what the Gain associated with each drug is. To do this, a synergistic combination of drugs will add (only for some pathogens and conditions) a small benefit. Appropriate antibiotic treatment is associated with a shorter stay in the hospital (by a median of one day) and, thus, with less expense.
Each drug has an associated cost, with contributions from cost of purchase, side effects, and development of future resistance. To calculate the net gain, i.e., the difference between Gain and Cost, we have used the common assumption in medicine that one life year is the equivalent of $55,000, this being the cost of keeping a patient with chronic renal failure on hemodialysis for one year.
COMMENTS
We have built a CPN to support decisions for treatment of bacterial infections. The CPN includes such elements that were thought by us to be crucial for the initial management of an infection. Our considerations included, from the beginning, availability of the data for the conditional probabilities tables, even if it meant sometimes giving up on fine modeling details. For example, a detailed causal model is available for the correlation between resistance to antibiotic drugs. Some of the correlation is explained by common mechanisms (e.g., an enzyme that can inactivate a whole family of antibiotics). Some is accounted for by linkage of genetic data on transposons and plasmids. However, data on the prevalence of these vectors in hospitals is lacking and we chose the less elegant solution of using a PU Â PU Â Q matrix for which data were available. The advantage of a causal net is that these avenues can be explored to generate and test hypotheses while using the present version for decision support.
The part of the net on systemic response to infection is a good example of that. We started with a statistical construct (factors derived by factor analysis) to reduce the dimensions of the matrix and to avoid repetitive donations of correlated variables. It turned out that the statistical factors have biological correspondences. We continue to develop this part of the net, not only as a support decision tool, but also to generate and test hypotheses on the clinical meaning of mediators in infection.
In many medical situations, we observe a number of manifestations, which are obviously correlated (e.g., all urinary complaints or septic manifestations). Counting them separately as evidence will induce bias. To reduce the dimensions of the matrix while retaining as much of the variance of the original dataset as possible (usually b VH percent), we used factor analysis. This technique builds a number of factors (fewer than the original number of variables), which represent correlations among the original variables. The factors are rotated so the contribution of the variables to factors will be as close as possible to H or AEI.The final factors are uncorrelated with each other [79] .
For our purposes, factor analysis offers a number of advantages. The donation of correlated variables is counted just once. Many times, the common factors correspond to a real biological vector. It also reduces the problem of missing data while using the system. (If a factor causes a number of manifestations, even if one of the manifestations is unobservable in a patient, the others will probably provide a good approximation as to the magnitude of the common factor). To our knowledge, factor analysis has not been used previously to shape a CPN from a database. We intend to explore if other ªdata miningº methods [80] , [81] will uncover the same structure of the CPN as the one derived by the use of factor analysis. Strictly speaking, the whole net is not a CPN, but is quite similar to an influence diagram [82] . Acknowledging the influence diagram tradition, we have used diamond shapes to represent utility nodes (Gain and Cost) and squares to represent decision nodes (Antibiotic_Tr). We have chosen not to call the net an influence diagram because we have used a different algorithm [22] to solve the influence diagram.
For accreting evidence, we used databases that were collected in two different countries at several locations and at different points in time and data from the literature. Many times publications supply different numbers for the same relation. To obtain one estimate from the published data, we weighted the parameters by inverse-variance, using a fixed-effect model [83] .
The databases that were used for extraction of data were analyzed before, using statistical methods. The ªknowl- edgeº incorporated in the CPN is both knowledge in the classical sense and insights derived from analysis of the databases. The causal network turned out to be an ideal tool for combining knowledge with data and data from several sources. There is no other methodology used for decision support in medicine that allows the combination of data from several sources with knowledge with such ease.
How convenient will it be to transfer and calibrate the system to another location? Although the data that was used to build it is extensive, we can state explicitly which data is needed to calibrate it to a new location ( Table 9 ). The data is available (or can be easily estimated) in most hospitals, often on magnetic media.
The main purpose in constructing the CPN was to use it in a DSS to improve treatment of infections. The first step before developing a DSS is to ask whether the problem we address is real, whether the decision-makers are in need of help, and what our criteria for improvement of process and outcome are. We have shown that the fatality associated with severe infections is substantial [6] , that it is reduced by appropriate antibiotic treatment regardless of other riskfactors for fatality [6] , [8] , [78] , and that the physicians often err in prescribing treatment. This situation involves an objective process variable (the rate of appropriate antibiotic treatments) and fatality can be used as the outcome variable.
The CPN addresses all the important decision-points in the first days of managing a patient suspected or known to have a bacterial infection (Table 10) . Based on previous experience [10] , [18] , [19] , we expect the CPN to perform better than the clinician, but will it improve clinical practice and patient's outcome? The answer probably depends on more factors than just the performance of the system. The user's interaction with the system should be as convenient as possible. In a computerized environment, most of the data can be imported into the system, saving the physician the need to enter it manually. The encounter between the user and the system can be initiated by the system, as well as by the user. In a computerized environment, the system can initiate an encounter if an antibiotic drug was prescribed, if growth was detected in a blood culture, or even if a patient with fever or other possible evidence of infection was entered into the hospital computerized database.
The ultimate question that must be answered is whether the system can be shown, in a clinical trial, to improve process and outcome variables, i.e., increase the percentage of appropriate antibiotic treatments, curtail costs and use of broad-spectrum antibiotics, reduce the fatality rate associated with infection, and curb progress of future resistance. 
